Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results
• Qualcomm (QCOM) call put ratio 4.8 calls to 1 put with a focus on September 11 weekly calls as share price up 4%
• Apple (AAPL) calls more active than puts into special event